Effect of Quadrivalent Human Papillomavirus Vaccination on Oral Squamous Cell Papillomas

Cyrus, Nika; Blechman, Adam B.; LeBoeuf, Matthew; Belyaeva, Elizaveta; Koning, Maurits N.C. de; Quint, Koen D.; Stern, John J.

doi:10.1001/jamadermatol.2015.2805

Cited by 19 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is because there are early data suggesting that men older than 26 years with anal HSIL may have a decreased risk of HSIL recurrence when they are given an adjuvant qHPV vaccine at the time of their HSIL treatment without the addition of any side effects. Others have reported similar evidence for decreasing rates of recurrent cervical intraepithelial neoplasia, vaginal intraepithelial neoplasia, and respiratory and laryngeal papillomatosis . Posttreatment adjuvant vaccination is not completely accepted in clinical practice because of the lack of randomized clinical trial data.…”

Section: Discussionmentioning

confidence: 97%

“…Others have reported similar evidence for decreasing rates of recurrent cervical intraepithelial neoplasia, vaginal intraepithelial neoplasia, and respiratory and laryngeal papillomatosis. [59][60][61][62][63][64][65][66] Posttreatment adjuvant vaccination is not completely accepted in clinical practice because of the lack of randomized clinical trial data. Furthermore, it is not understood whether the vaccine prevents the recurrence of the initially treated lesion or halts new HSIL development.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Management of precancerous anal intraepithelial lesions in human immunodeficiency virus–positive men who have sex with men: Clinical effectiveness and cost‐effectiveness

Deshmukh

Chiao

Cantor

et al. 2017

Cancer

View full text Add to dashboard Cite

BACKGROUND: Human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) are at disproportionately high risk for anal cancer. There is no definitive approach to the management of high-grade squamous intraepithelial lesions (HSIL), which are precursors of anal cancer, and evidence suggests that posttreatment adjuvant quadrivalent human papillomavirus (qHPV) vaccination improves HSIL treatment effectiveness. The objectives of this study were to evaluate the optimal HSIL management strategy with respect to clinical effectiveness and cost-effectiveness and to identify the optimal age for initiating HSIL management. METHODS: A decision analytic model of the natural history of anal carcinoma and HSIL management strategies was constructed for HIV-positive MSM who were 27 years old or older. The model was informed by the Surveillance, Epidemiology, and End Results-Medicare database and published studies. Outcomes included the lifetime cost, life expectancy, quality-adjusted life expectancy, cumulative risk of cancer and cancer-related deaths, and cost-effectiveness from a societal perspective. RESULTS: Active monitoring was the most effective approach in patients 29 years or younger; thereafter, HSIL treatment plus adjuvant qHPV vaccination became most effective. When cost-effectiveness was considered (ie, an incremental cost-effectiveness ratio [ICER] < $100,000/quality-adjusted life-year), do nothing was cost-effective until the age of 38 years, and HSIL treatment plus adjuvant qHPV vaccination was cost-effective beyond the age of 38 years (95% confidence interval, 34-43 years). The ICER decreased as the age at HSIL management increased. Outcomes were sensitive to the rate of HSIL regression or progression and the cost of high-resolution anoscopy and biopsy. CON-CLUSIONS: The management of HSIL in HIV-positive MSM who are 38 years old or older with treatment plus adjuvant qHPV vaccination is likely to be cost-effective. The conservative approach of no treatment is likely to be cost-effective in younger patients. Cancer 2017;123:4709-19.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Management of precancerous anal intraepithelial lesions in human immunodeficiency virus–positive men who have sex with men: Clinical effectiveness and cost‐effectiveness

Deshmukh

Chiao

Cantor

et al. 2017

Cancer

View full text Add to dashboard Cite

show abstract

“…14 Regarding the oral cavity, until 2015, only 9 cases have been reported in which the quadrivalent vaccine was applied in patients with oral lesions associated with HPV, with encouraging results in short-term patients, however in patients with immune alterations, the effectiveness of the vaccine on present lesions decreases considerably. 15 Despite this, in the preventive field, in the few studies that are being carried out to date, a reduction in the prevalence of oral HPV 16 -18 lesions is observed among vaccinated women, however, are still questioned because the indication of the vaccine is based on the epidemiology of HPV in the cervix, so it is necessary to carry out studies that provide definitive evidence for the use of the vaccine as a method preventive in the development of oral cancer. 14…”

Section: Discussionmentioning

confidence: 99%

Squamous papilloma in the oral cavity: case presentation and review of the literature

Alvarado

Rodríguez

Carrasco

et al. 2018

JDHODT

View full text Add to dashboard Cite

Oral Squamous Papilloma is the most common benign tumor that can be found in the oral cavity, the main etiological factor is Human Papilloma Virus (HPV), the route of transmission of this virus is through direct contact, despite being a lesion with benign characteristics, it has been observed in recent years that HPV infection is directly associated with the presence of Squamous Cell Carcinoma in the oral cavity, becoming a factor of importance that must be addressed by the different health services worldwide. We present the case of a 63-year-old male patient who attended the Dental Clinic of the Faculty of Dentistry of the Pontificia Universidad Javeriana Bogotá-Colombia. Through the intraoral examination, a papillary lesion on the soft palate was found. An excisional biopsy was performed and the diagnosis is confirmed by histopathological examination.

show abstract

“…1 Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) induced by mogamulizumab have been reported. [1][2][3][4] Here, we report a patient who developed SJS during mogamulizumab treatment for ATL.…”

Section: Depletion Of Regulatory Foxp3 + T Cells In the Pathogenesis mentioning

confidence: 94%

“…Although the vaccine was not shown to prevent progress of cervical neoplasia, few case reports and small studies suggested that HPV vaccine may be used as an adjuvant therapy for common and genital warts and oral papillomatosis. [1][2][3][4] Herein, we present an example of complete elimination of giant condyloma after only one dose of 9-valent HPV vaccine.…”

Section: Regression Of Giant Condyloma Acuminata After One Dose Of 9-mentioning

confidence: 99%

Regression of giant condyloma acuminata after one dose of 9‐valent human papillomavirus (HPV) vaccine

Kazlouskaya

Fiadorchanka

2019

Int J Dermatology

View full text Add to dashboard Cite

Effect of Quadrivalent Human Papillomavirus Vaccination on Oral Squamous Cell Papillomas

Cited by 19 publications

References 15 publications

Management of precancerous anal intraepithelial lesions in human immunodeficiency virus–positive men who have sex with men: Clinical effectiveness and cost‐effectiveness

Management of precancerous anal intraepithelial lesions in human immunodeficiency virus–positive men who have sex with men: Clinical effectiveness and cost‐effectiveness

Squamous papilloma in the oral cavity: case presentation and review of the literature

Regression of giant condyloma acuminata after one dose of 9‐valent human papillomavirus (HPV) vaccine

Contact Info

Product

Resources

About